Dihexa Dosage Guide

Dihexa was developed by researchers at Washington State University led by Dr. Joseph Harding and Dr. John Wright. It is a modified hexapeptide analog of angiotensin IV that acts as a potent hepatocyte growth factor (HGF) / c-Met receptor agonist.

In preclinical studies, Dihexa was found to be approximately 10 million times more potent than BDNF in promoting new synapse formation (synaptogenesis). It demonstrated the ability to cross the blood-brain barrier when administered orally or intranasally, and improved cognitive function in animal models of dementia. These findings were published in the Journal of Pharmacology and Experimental Therapeutics (2013).

Dihexa is an extremely potent compound requiring very low doses. Research protocols are extrapolated from animal studies:

Note: Dihexa dosing in human subjects lacks clinical trial data. All doses are extrapolated from animal research and anecdotal reports. Extreme caution is warranted due to the compound's extraordinary potency.

Dihexa is typically administered once daily due to its sustained mechanism of action (synaptogenesis is a slow process):

• Morning dosing: Most common, as cognitive enhancement is the primary research goal.
• With or without food: Oral bioavailability data in humans is limited. Some protocols suggest taking on an empty stomach for optimal absorption.

Cycling: Due to limited safety data, conservative cycling is strongly recommended: 2–4 weeks on, followed by an equal or longer break. Some protocols limit use to 30 days maximum per cycle. Synaptogenic effects may persist after discontinuation as newly formed synapses are maintained.

Dihexa is available as a powder or in pre-made oral/sublingual solutions:

• Oral capsules: Swallow with water. Standard capsule doses are 10 mg or 20 mg.
• Sublingual solution: Place under the tongue and hold for 60 seconds before swallowing. This route may provide faster onset and higher bioavailability.
• Intranasal: Dissolve in bacteriostatic water at a known concentration. Administer via calibrated nasal spray. This route bypasses first-pass metabolism.

Dihexa does not require injection-based administration, making it unique among research peptides. Store in a cool, dry place. Protect from light and moisture.

• 5–10 mg oral: Limited side effect data available. Anecdotal reports include mild headache, increased dream vividness, and enhanced emotional sensitivity.
• 10–20 mg oral: Reports of overstimulation, anxiety, or difficulty sleeping in some individuals. Enhanced emotional processing may be dysphoric for some.
• Higher doses: Unknown territory. No published safety data at higher doses.

Critical concern: Dihexa's mechanism as an HGF/c-Met agonist raises theoretical oncological concerns, as the HGF/c-Met pathway is frequently dysregulated in cancers. Long-term safety is completely unknown.

Dihexa is an experimental research compound with NO clinical trials in humans. It is not FDA-approved and should be considered investigational only.

The HGF/c-Met pathway is implicated in cancer progression — Dihexa is absolutely contraindicated in subjects with any active or suspected malignancy. Due to the complete absence of human safety data, extreme caution is warranted. Use only under medical supervision with informed consent. Start with the lowest possible dose.